A K Dewan1, L Sowerby1, S Jadeja2, C Lian2, P Wen3, J R Brown4, D C Fisher5, N R LeBoeuf1. 1. Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 3. Department of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 4. Chronic Lymphocytic Leukemia Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
BACKGROUND: Phosphoinositide 3-kinase (PI3K) inhibitors are a class of small-molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described. AIM: To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. METHODS: This was a retrospective analysis of patients receiving PI3K inhibitors referred to the Skin Toxicities Program in The Center for Cutaneous Oncology. RESULTS: Three patients on PI3K inhibitors for treatment of malignancy developed diffuse erythroderma and keratoderma. Clinical and histopathological findings were consistent with pityriasis rubra pilaris (PRP)-like reactions. All patients improved with topical and oral corticosteroids, oral acitretin, and drug discontinuation. CONCLUSIONS: PRP-like cutaneous eruptions may develop secondary to PI3K inhibition. Early dermatological evaluation of cutaneous toxicities to PI3K inhibitors as well as rapid initiation of disease-specific treatments may help keep patients on life-prolonging anti-cancer therapies.
BACKGROUND:Phosphoinositide 3-kinase (PI3K) inhibitors are a class of small-molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described. AIM: To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. METHODS: This was a retrospective analysis of patients receiving PI3K inhibitors referred to the Skin Toxicities Program in The Center for Cutaneous Oncology. RESULTS: Three patients on PI3K inhibitors for treatment of malignancy developed diffuse erythroderma and keratoderma. Clinical and histopathological findings were consistent with pityriasis rubra pilaris (PRP)-like reactions. All patients improved with topical and oral corticosteroids, oral acitretin, and drug discontinuation. CONCLUSIONS:PRP-like cutaneous eruptions may develop secondary to PI3K inhibition. Early dermatological evaluation of cutaneous toxicities to PI3K inhibitors as well as rapid initiation of disease-specific treatments may help keep patients on life-prolonging anti-cancer therapies.
Authors: Johanna C Bendell; Jordi Rodon; Howard A Burris; Maja de Jonge; Jaap Verweij; Diana Birle; David Demanse; Stefan S De Buck; Qinhua C Ru; Malte Peters; Michael Goldbrunner; José Baselga Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Benjamin L Lampson; Siddha N Kasar; Tiago R Matos; Elizabeth A Morgan; Laura Rassenti; Matthew S Davids; David C Fisher; Arnold S Freedman; Caron A Jacobson; Philippe Armand; Jeremy S Abramson; Jon E Arnason; Thomas J Kipps; Joshua Fein; Stacey Fernandes; John Hanna; Jerome Ritz; Haesook T Kim; Jennifer R Brown Journal: Blood Date: 2016-05-31 Impact factor: 22.113
Authors: Brad S Kahl; Stephen E Spurgeon; Richard R Furman; Ian W Flinn; Steven E Coutre; Jennifer R Brown; Don M Benson; John C Byrd; Sissy Peterman; Yoonjin Cho; Albert Yu; Wayne R Godfrey; Nina D Wagner-Johnston Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud Journal: Lancet Date: 2008-07-22 Impact factor: 79.321
Authors: Jean Christopher Chamcheu; Maria-Ines Chaves-Rodriquez; Vaqar M Adhami; Imtiaz A Siddiqui; Gary S Wood; B Jack Longley; Hasan Mukhtar Journal: Acta Derm Venereol Date: 2016-08-23 Impact factor: 4.437